Core Viewpoint - The company reported a significant decline in revenue and profit for the nine months ending September 30, 2025, primarily due to decreased sales in intravenous infusion and ampoule injection products, alongside intensified price pressures from expanded procurement initiatives and increased competition in the industry [1] Financial Performance - The company's unaudited revenue for the nine months ending September 30, 2025, was approximately HKD 3.102 billion, representing a year-on-year decrease of 31.6% [1] - The unaudited gross profit for the same period was approximately HKD 1.294 billion, down 46.1% year-on-year, with a gross profit margin of 41.7%, a decline of 11.3 percentage points compared to the previous year [1] - The unaudited profit attributable to shareholders for the nine months was approximately HKD 399 million, reflecting a year-on-year decrease of 56.6% [1]

石四药集团(02005)发布截至2025年9月30日止9个月业绩，以港元而言，集团截至2025年9月30日止9个 月的未经审核营业额约31.02亿港元，同比减少31.6%(集团截至2025年6月30日止6个月的收益:同比减少 35.7%)，主要由于静脉输液的销量及安瓿注射液的未经审核营业额下降。各种形式的带量采购(包括国 家集采及地方联盟集采)范围扩大以及国内外行业竞争加剧带来持续的价格压力。集团截至2025年9月30 日止9个月的未经审核毛利约12.94亿港元，同比减少46.1%，其未经审核毛利率约为41.7%，同比减少 11.3百分点。截至2025年9月30日止9个月，集团的未经审核公司股东应占溢利约3.99亿港元，同比减少 56.6%(2025年上半年的股东应占溢利:同比减少58.7%)。 ...